Overview
A secondary analysis of a randomized controlled trial published in Behaviour Research and Therapy found that somnovia, GAIA’s digital insomnia therapy, primarily improves chronic insomnia by reducing hyperarousal.
The study showed that targeting hyperarousal not only improves sleep but also contributes to reductions in depressive and anxiety symptoms over time.
The findings strengthen the clinical evidence supporting somnovia, which is permanently listed in Germany’s DiGA directory and reimbursed by all statutory health insurance providers.
The News
GAIA has published a secondary analysis of a randomized controlled trial in Behaviour Research and Therapy revealing that somnovia, its digital cognitive behavioral therapy for insomnia (CBT-I), exerts its therapeutic effects by reducing hyperarousal—a key transdiagnostic process linked to insomnia, depression, and anxiety. The analysis included data from 290 adults with chronic insomnia who received either somnovia alongside treatment as usual (TAU) or TAU alone. Using Network Intervention Analysis, researchers found that after three months, the therapy significantly improved hyperarousal-related symptoms, including difficulty relaxing, sleep-related worries, dissatisfaction with sleep quality, and psychomotor restlessness. By six months, these benefits extended across broader symptom networks, reducing depressive and anxiety symptoms. Somnovia is a fully self-guided, web-based CBT-I program incorporating sleep restriction, stimulus control, sleep hygiene, mindfulness, relaxation, and cognitive techniques. The therapy is permanently listed in Germany’s DiGA directory, allowing physicians and psychotherapists to prescribe it with reimbursement through statutory health insurance.
Industry Perspective
Digital cognitive behavioral therapy is increasingly recognized as an effective solution for addressing the growing burden of chronic insomnia, particularly where access to in-person therapy remains limited. As research expands beyond clinical outcomes to explore mechanisms of action, digital therapeutics are demonstrating broader benefits for mental health by targeting shared pathways across multiple psychological conditions.
Strategic Impact
The study provides mechanistic evidence supporting somnovia’s role as more than a sleep therapy, highlighting its potential to improve coexisting depression and anxiety through targeting hyperarousal. These findings reinforce the value of reimbursable digital therapeutics in routine clinical care and strengthen GAIA’s evidence base as it continues expanding clinically validated digital mental health solutions.
Source: GAIA
